WO2000044775A3 - Identification of broadly reactive hla restricted t cell epitopes - Google Patents

Identification of broadly reactive hla restricted t cell epitopes Download PDF

Info

Publication number
WO2000044775A3
WO2000044775A3 PCT/US2000/001918 US0001918W WO0044775A3 WO 2000044775 A3 WO2000044775 A3 WO 2000044775A3 US 0001918 W US0001918 W US 0001918W WO 0044775 A3 WO0044775 A3 WO 0044775A3
Authority
WO
WIPO (PCT)
Prior art keywords
supermotifs
identification
cell epitopes
broadly reactive
hla restricted
Prior art date
Application number
PCT/US2000/001918
Other languages
French (fr)
Other versions
WO2000044775A2 (en
Inventor
Alessandro Sette
John Sidney
Original Assignee
Epimmune Inc
Alessandro Sette
John Sidney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc, Alessandro Sette, John Sidney filed Critical Epimmune Inc
Priority to AU32158/00A priority Critical patent/AU3215800A/en
Publication of WO2000044775A2 publication Critical patent/WO2000044775A2/en
Publication of WO2000044775A3 publication Critical patent/WO2000044775A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This application discloses five new amino acid supermotifs and corresponding grouping of HLA molecules (i.e., HLA supertypes that bind peptides that bear these supermotifs). Peptides epitopes bearing these supermotifs are selected for use in vaccines and other pharmaceutical compositions. The new supermotifs are used to screen known disease-related targets, as well as targets that will be determined in the future.
PCT/US2000/001918 1999-01-27 2000-01-26 Identification of broadly reactive hla restricted t cell epitopes WO2000044775A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32158/00A AU3215800A (en) 1999-01-27 2000-01-26 Identification of broadly reactive hla restricted t cell epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11748699P 1999-01-27 1999-01-27
US60/117,486 1999-01-27

Publications (2)

Publication Number Publication Date
WO2000044775A2 WO2000044775A2 (en) 2000-08-03
WO2000044775A3 true WO2000044775A3 (en) 2000-11-30

Family

ID=22373213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001918 WO2000044775A2 (en) 1999-01-27 2000-01-26 Identification of broadly reactive hla restricted t cell epitopes

Country Status (2)

Country Link
AU (1) AU3215800A (en)
WO (1) WO2000044775A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
AU2002239410B2 (en) 2000-10-31 2008-05-01 Eisai Inc. CYP1B1 nucleic acids and methods of use
AU2002309873B2 (en) * 2001-05-15 2007-10-18 Agensys, Inc. Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2345420B1 (en) 2003-03-24 2016-01-06 Valneva Austria GmbH Use of a TH1 immune response inducing adjuvant for enhancing immune responses
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003140A1 (en) * 1994-07-21 1996-02-08 Cytel Corporation HLA binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003140A1 (en) * 1994-07-21 1996-02-08 Cytel Corporation HLA binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes

Also Published As

Publication number Publication date
AU3215800A (en) 2000-08-18
WO2000044775A2 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
DK1042355T3 (en) 11beta-halo-7alpha-substituted estratrienes, process for the preparation of pharmaceutical compositions containing these 11beta-halo-7alpha-substituted estratrienes, and their use in the manufacture of pharmaceuticals
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2006094093A3 (en) A method for identifying skin care composition-resistant skin-binding peptides
AU6267000A (en) Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
CN101687915B8 (en) Cross-species-specific cd 3-epsilon binding domain
BR0209689A (en) Use of hmg fragment as anti-inflammatory agent
WO2006105112A3 (en) Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
WO2006074051A3 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
EP1736627A3 (en) Sprung hinge for supporting a closure element
WO2002039998A3 (en) Methods and compositions for regulating memory consolidation
WO2008020335A8 (en) Immunogenic compositions for streptococcus agalactiae
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
WO2005058356A3 (en) Methods for porducing storage stable viruses and immunogenic compositions thereof
CA2295321A1 (en) Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
WO2000044775A3 (en) Identification of broadly reactive hla restricted t cell epitopes
SE0003538D0 (en) New immunogenic complex
EP1469886B8 (en) Lyophilized pharmaceutical composition of propofol
WO2003037370A3 (en) Anthrax antigenic compositions
WO2002049625A3 (en) Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
TW200701258A (en) Ionic material and application thereof
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
丰德军 et al. The net measure properties of symmetric Cantor sets and their applications
WO2005105899A3 (en) Gel with a high concentration of branched sulphonic polyester and method for preparing same
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase